Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: a real-life observational study in Greece
A Tzouvelekis, T Karampitsakos, M Kontou… - Pulmonary …, 2018 - Elsevier
Background Nintedanib represents an antifibrotic compound able to slow down disease
progression of patients with idiopathic pulmonary fibrosis (IPF). Objective To investigate the …
progression of patients with idiopathic pulmonary fibrosis (IPF). Objective To investigate the …
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
HY Yoon, S Park, DS Kim, JW Song - Respiratory research, 2018 - Springer
Background Phase 3 trials have shown that nintedanib reduces the decline in forced vital
capacity (FVC) in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF) with …
capacity (FVC) in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF) with …
Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study
K Antoniou, K Markopoulou, A Tzouvelekis… - ERJ open …, 2020 - Eur Respiratory Soc
Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary
fibrosis (IPF). In a retrospective, real-world study across seven Greek hospitals, we …
fibrosis (IPF). In a retrospective, real-world study across seven Greek hospitals, we …
[HTML][HTML] Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials
Abstract Background and purpose The Phase II TOMORROW trial and two Phase III
INPULSIS® trials investigated the efficacy and safety of nintedanib versus placebo in …
INPULSIS® trials investigated the efficacy and safety of nintedanib versus placebo in …
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week
period followed by a further blinded treatment period and an open-label extension. We …
period followed by a further blinded treatment period and an open-label extension. We …
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
T Corte, F Bonella, B Crestani, MG Demedts… - Respiratory …, 2015 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterised by
dyspnea and loss of lung function. Methods Using pooled data from the replicate …
dyspnea and loss of lung function. Methods Using pooled data from the replicate …
Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
I Glaspole, F Bonella, E Bargagli, MK Glassberg… - Respiratory …, 2021 - Springer
Background Idiopathic pulmonary fibrosis (IPF) predominantly affects individuals aged> 60
years who have several comorbidities. Nintedanib is an approved treatment for IPF, which …
years who have several comorbidities. Nintedanib is an approved treatment for IPF, which …
[HTML][HTML] A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world
M Nakamura, M Okamoto, K Fujimoto… - Annals of …, 2019 - ncbi.nlm.nih.gov
Background Nintedanib is a tyrosine kinase inhibitor that has been shown to suppress
progression of idiopathic pulmonary fibrosis (IPF). The efficacy and tolerability of nintedanib …
progression of idiopathic pulmonary fibrosis (IPF). The efficacy and tolerability of nintedanib …
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
L Lancaster, B Crestani… - BMJ open …, 2019 - bmjopenrespres.bmj.com
Introduction Nintedanib slows disease progression in patients with idiopathic pulmonary
fibrosis (IPF) by reducing the rate of decline in forced vital capacity, with an adverse event …
fibrosis (IPF) by reducing the rate of decline in forced vital capacity, with an adverse event …
Real-world safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: interim report of a post-marketing surveillance in Japan
T Ogura, Y Inoue, A Azuma, S Homma, Y Kondoh… - Advances in …, 2023 - Springer
Introduction Nintedanib is recommended for the treatment of idiopathic pulmonary fibrosis
(IPF); however, treatment discontinuation due to adverse events (AEs) is common. A large …
(IPF); however, treatment discontinuation due to adverse events (AEs) is common. A large …